Zhang Li, Yang Jian, Li Jun-Jie, Chen Chi-Yi, Wang Xiao-Dong, Xie Yan, Jiang Wen-Tao
Department of Liver Transplantation, Tianjin First Center Hospital, Tianjin 300192, China.
World J Clin Oncol. 2025 Apr 24;16(4):100729. doi: 10.5306/wjco.v16.i4.100729.
Hepatocellular carcinoma (HCC) ranks as the sixth most common cancer and the third- leading cause of cancer-related deaths worldwide. The multidisciplinary tumor board (MDTB) has been recognized for improving outcomes in cancer management, but its role in patients with HCC undergoing liver transplantation (LT) remains underexplored.
To evaluate the impact of an MDTB on survival outcomes in patients with HCC undergoing LT.
We retrospectively analyzed 393 patients with HCC who underwent LT at our institution from October 2015 to October 2021. Patients were categorized into the MDTB and non-MDTB groups. We compared preoperative and postoperative characteristics, overall survival (OS), and disease-free survival (DFS) between the two groups.
Within the University of California, San Francisco (UCSF) criteria, no significant differences in OS and DFS were noted between the MDTB and non-MDTB groups. However, for patients who exceeded the UCSF criteria, the MDTB group exhibited a substantial improvement in both OS and DFS. The 1-year, 3-year, and 5-year OS rates for the MDTB group in this subgroup were 88.68%, 75.29%, and 61.78%, respectively, compared to 83.02%, 64.07%, and 38.25%, respectively in the non-MDTB group. Similarly, DFS rates were 89.47%, 71.35%, and 63.52%, respectively, 82.18%, 53.78%, and 34.04%, respectively.
The MDTB approach was particularly beneficial for patients with HCC exceeding the UCSF criteria, significantly improving OS and DFS. These findings advocate for integrating MDTB into clinical practice for optimizing the management of high-risk patients with HCC undergoing LT.
肝细胞癌（HCC）是全球第六大常见癌症，也是癌症相关死亡的第三大主要原因。多学科肿瘤委员会（MDTB）已被认可可改善癌症管理的结果，但其在接受肝移植（LT）的HCC患者中的作用仍未得到充分探索。
评估MDTB对接受LT的HCC患者生存结果的影响。
我们回顾性分析了2015年10月至2021年10月在我院接受LT的393例HCC患者。患者被分为MDTB组和非MDTB组。我们比较了两组患者术前和术后的特征、总生存期（OS）和无病生存期（DFS）。
在加利福尼亚大学旧金山分校（UCSF）标准范围内，MDTB组和非MDTB组在OS和DFS方面无显著差异。然而，对于超过UCSF标准的患者，MDTB组在OS和DFS方面均有显著改善。该亚组中MDTB组的1年、3年和5年OS率分别为88.68%、75.29%和61.78%，而非MDTB组分别为83.02%、64.07%和38.25%。同样，DFS率分别为89.47%、71.35%和63.52%，非MDTB组分别为82.18%、53.78%和34.04%。
MDTB方法对超过UCSF标准的HCC患者特别有益，显著改善了OS和DFS。这些发现主张将MDTB纳入临床实践，以优化接受LT的高危HCC患者的管理。
